The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer

Journal of the American College of Nutrition

Volumn 22, Issue 2, 2003, Pages 118-123

  Chapman, Julia ^a   Hunter, Verda J ^a   Drisko, Jeanne A ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidants; Carotenoids; Chemotherapy; Ovarian cancer; Vitamin A; Vitamin C; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CARBOPLATIN; MULTIVITAMIN; PACLITAXEL; UBIDECARENONE;

ADULT; ADVANCED CANCER; ALTERNATIVE MEDICINE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASE REPORT; DRUG MEGADOSE; DYSPNEA; FATIGUE; FEMALE; HUMAN; NEUTROPENIA; OVARY ADENOCARCINOMA; OVARY CANCER; PARESTHESIA; PERIPHERAL EDEMA; SKIN TINGLING; THROMBOCYTOPENIA;

ADENOCARCINOMA, PAPILLARY; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; CARBOPLATIN; COMPLEMENTARY THERAPIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME; VITAMINS;

FALLOPIA;

EID: 0037390486     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2003.10719284     Document Type: Article

References (36)

1. Markman M: Ovarian cancer update: Management challenges and advances. Cleve Clin J Med 61:51-58, 1994.
2. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin 46:5-27, 1996.
3. Williams T, O'Sullivan M, Snodgrass S, Love N: Psychosocial issues in breast cancer: helping patients get the support they need. Postgrad Med 98:97-110, 1995.
4. Cassileth B, Chapman C: Alternative cancer medicine: a ten-year update. Cancer Invest 14:396-404, 1996.
5. VandeCreek L, Rogers E, Lester J: Use of Alternative therapies among breast cancer outpatients compared with the general population. Alt Ther Health Disease 5:71-76, 1999.
6. Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 83: 777-782, 1998.
7. Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Garvin A, Baron RA, Aaron D, Haines-Kamka T: Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18: 2515-2521, 2000.
8. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE: Complementary/Alternative Medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505-2514, 2000.
9. Riordan NH, Riordan HD, Meng YL, Jackson JA: Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses 44:207-213, 1995.
10. Riordan NH, Riordan HD, Casciari JP: Clinical and experimental experiences with intravenous vitamin C. J Orthomol Med 5:201-213, 2000.
11. Prasad KN, Cole WC, Kumar B, Prasad KC: Scientific rationale for using high-dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. J Am Coll Nutr 20: 450S-463S, 2001.
12. Weijl NI, Cleton FJ, Osanto S: Free radicals and antioxidants in chemotherapy induced toxicity. Cancer Treat Res 23:209-240, 1997.
13. Lamson DW, Brignall MS: Antioxidants in cancer therapy: their actions and interactions with oncologic therapies. Alt Med Rev 4:304-329, 1999.
14. Schmitt CA, Lowe SW: Apoptosis and therapy. J Pathol 187:127-137, 1999.
15. Prasad KN, Kumar A, Kochupillai V, Cole WC: High doses of multiple antioxidant vitamins: essential ingredients in improving the efficacy of standard cancer therapy. J Am Coll Nutr 18:13-25, 1999.
16. Chinery R, Brockman JA, Peeler MO, Shyr Y, Beauchamp RD, Coffey RJ: Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBP_. Nat Med 3:1233-1241, 1997.
17. Agus DB, Vers JC, Golde DW: Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res 59:4555-4558, 1999.
18. Prasad KN, Hernandez C, Edwards-Prasad J, Nelson J, Borus T, Robinson WA: Modification of the effect of tamoxifen, cisplatin, DTIC and interferon-2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer 22:233-245, 1994.
19. Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Nat Acad Sci 73:3685-3689, 1976.
20. Lupulescu A: Ultrastructure and cell surface studies of cancer cells following vitamin C administration. Exp Toxic Pathol 4:3-9, 1992.
21. Cameron E, Pauling L: The orthomolecular treatment of cancer. 1. The role of ascorbate in host resistance. Chem Biol Interact 9:273-283, 1974.
22. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, Frytak S: Failure of high dose vitamin C (ascorbic acid) to benefit patients with advanced cancer: a controlled trial. N Engl J Med 301:687-690, 1979.
23. Murata A, Morishige F, Yamaguchi H: Prolongation of survival times of terminal cancer patients by the administration of large doses of ascorbate. In Hanck A (ed): "Vitamin C: New Clinical Applications in Immunology, Lipid Metabolism and Cancer." Bern: Huber, pp 103-113, 1982.
24. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM: High dose vitamin C versus placebo in the treatment of patients with advanced cancer who had had no prior chemotherapy: A randomized double-blind comparison. N Engl J Med 312:137-141, 1985.
25. Vojdani A: Enhancement of natural killer cell activity and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals: the role of protein kinase C. Immunopharm Immunotox 19:291-312, 1997.
26. Vojdani A: In vivo effect of ascorbic acid on enhancement of natural killer cell activity. Nutr Res 13:753-764, 1993.
27. Roomi MW, House D, Eckert-Maksic M, Maksic ZB, Tsao CS: Growth suppression of malignant leukemia cell line in vitro by ascorbic acid (vitamin C) and its derivatives. Cancer Lett 22:3-99, 1998.
28. Benade L, Howard T, Burk D: Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3 amino-1,2,4-triazole. Oncology 23:33-43, 1969.
29. Park CH, Amare M, Savin MA, Hoogstraten B: Growth suppression of human leukemic cells in vitro by L-ascorbic acid. Cancer Res 40:1062-1065, 1980.
30. Teicher BA, Schwartz JL, Holden SA, Ara G, Northey D: In vivo modulation of several anticancer agents by b-carotene. Cancer Chemother Pharmacol 34:235-241, 1994.
31. Alpha-tocopherol, Beta-carotene Prevention Study Group: The effects of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. New Engl J Med 330:1029-1035, 1994.
32. Mackerras D, Irwig L, Simpson JM, Weisberg E, Cardona M, Webster F, Walton L, Ghersi D: Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities. Br J Cancer 79:1448-1453, 1999.
33. Prasad KN, Edwards-Prasad J: Vitamin E and cancer prevention: recent advances and future potentials. J Am Coll Nutr 11:487-500, 1992.
34. Cole WC, Prasad KN: Contrasting effects of vitamins as modulators of apoptosis in cancer cells and normal cells: a review. Nutr Cancer 29:97-103, 1997.
35. Seifter E, Returra A, Padawar J, Levenson SM: Vitamin A and a-carotene as adjunctive therapy to tumor excision, radiation therapy, and chemotherapy. In Prasad KN (ed): "Vitamins, Nutrition, and Cancer." Basel: Karger, pp 1-19, 1984.
36. Prasad KN, Edwards-Prasad J: Expressions of some molecular cancer risks factors and their modification by vitamins. J Am Coll Nutr 9:28-34, 1990.